semaglutide in heart failure #hfpef #obesity #esccongress | European Society of Cardiology Semaglutide Reduces Need for Diuretics

A systematic review of honey uses and its potential value within oncology care

45 Products that are a combination of a DPP-4 inhibitor and an SGLT2 inhibitor (sitagliptin/ertugliflozin, saxagliptin/dapagliflozin, and linagliptin/empagliflozin) may be used to further lower A1C and provide increased CV benefit in patients who are not meeting A1C goals on dual therapy

systemic form of RUO

This weekly dosing schedule offers a streamlined and convenient option for patients, removing the need for daily injections while maintaining consistent therapeutic benefits

It is worth noting that for currently licensed GLP-1 receptor agonists in the UK, the thyroid tumour signal is classified as a precautionary consideration based on rodent data, rather than a formal contraindication as reflected in UK Summaries of Product Characteristics (SmPCs)

Its dosing schedules, batch stability data, and arm designs now serve as protocol templates for Canadian metabolic labs